Breaking News
Get 50% Off 0
📌 New AI-picked stocks coming soon. 3 picks from last month are already up +30%...
Get early access
Close

Chugai Pharmaceutical Co., Ltd. (4519)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
7,406.0 +31.0    +0.42%
07:30:29 - Closed. Currency in JPY
Type:  Equity
Market:  Japan
ISIN:  JP3519400000 
  • Volume: 2,829,300
  • Bid/Ask: 7,405.0 / 7,435.0
  • Day's Range: 7,079.0 - 7,496.0
Chugai Pharmaceutical 7,406.0 +31.0 +0.42%

Chugai Pharmaceutical Co., Ltd. Company Profile

 
Get an in-depth profile of Chugai Pharmaceutical Co., Ltd., including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

5026

Equity Type

ORD

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; research collaboration and option to license agreement with Araris Biotech AG to develop ADCs using Araris AraLinQ technology; and research and license agreement with Gero PTE. LTD. to develop novel therapies for age-related diseases. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. Chugai Pharmaceutical Co., Ltd. was founded in 1925 and is headquartered in Chuo-ku, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

Contact Information

Address Nihonbashi Mitsui Tower Reception12F
1-1 Nihonbashi-Muromachi 2-chome Chuo, 103-8324
Japan
Phone 81 3 3281 6611
Fax 81 3 3281 6607

Top Executives

Name Age Since Title
Shigehiro Yamada 60 2019 Full-Time Audit & Supervisory Board Member
Iwaaki Taniguchi 57 2022 Executive VP, Head of Finance Supervisory Division, CFO & Director
Kenichi Masuda 62 2020 Outside Independent Audit & Supervisory Board Member
William A. M. Burns 78 - Member of the International Advisory Council
Fumio Tateishi 76 2023 Outside Independent Director
Hideo Teramoto 65 2023 Outside Independent Director
Andrew C. von Eschenbach 83 - Member of the International Advisory Council
Sonosuke Kadonaga 73 - Member of the International Advisory Council
Teresa A. Graham 52 2023 Non-Executive Director
Yumiko Waseda 65 2023 Outside Independent Audit & Supervisory Board Member
Mami Yunoki 62 2024 Outside Independent Audit & Supervisory Board Member
Victor Halberstadt - - Member of the International Advisory Council
Franz Bernhard Humer 79 2014 Member of the International Advisory Council
Arnold J. Levine 85 - Member of the International Advisory Council
Henry L. Nordhoff 83 - Chairman of the International Advisory Council
Virginia Hilda Brunette Maxwell Bottomley 77 - Member of the International Advisory Council
Mariko Y. Momoi 77 2020 Outside Independent Director
Boris L. Zaitra 53 2025 Director
Hitoshi Iikura 55 2024 Executive VP, Head of Translational Research Division & Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

4519 Comments

Write your thoughts about Chugai Pharmaceutical Co., Ltd.
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email